2026-05-04T16:55:44Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/204762024-11-28T19:50:33Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16976

00925njm 22002777a 4500 dc Bautista, Francisco author Gallego, Soledad author Canete, Adela author Mora, Jaume author Diaz de Heredia, Cristina author Cruz, Ofelia author Maria Fernandez, Jose author Rives, Susana author Berlanga, Pablo author Hladun, Raquel author Juan Ribelles, Antonio author Madero, Luis author Ramirez, Manuel author Fernandez Delgado, Rafael author Perez-Martinez, Antonio author Mata, Cristina author Llort, Anna author Martin Broto, Javier author Elena Cela, Maria author Ramirez, Gema author Sabado, Constantino author Acha, Tomas author Astigarraga, Itziar author Sastre, Ana author Munoz, Ascension author Guibelalde del Castillo, Mercedes author Sociedad Espanola Hematologia author New Drug Dev Grp Pediat Oncology author 2017-09 Introduction: Cancer is the leading cause of death between the first year of life and adolescence, and some types of diseases are still a major challenge in terms of cure. There is, therefore, a major need for new drugs. Recent findings in cancer biology open the door to the development of targeted therapies against individual molecular changes, as well as immunotherapy. Promising results in adult anti-cancer drug development have not yet been translated into paediatric clinical practice. A report is presented on the activity in early paediatric oncology trials (phase I-II) in Spain. Material and methods: All members of the Spanish Society of Paediatric Haematology Oncology (SEHOP) were contacted in order to identify early clinical trials in paediatric cancer opened between 2005 and 2015. Results: A total of 30 trials had been opened in this period: 21 (70%) in solid tumours, and 9 (30%) in malignant haemopathies. A total of 212 patients have been enrolled. The majority was industry sponsored (53%). Since 2010, four centres have joined the international consortium of Innovative Therapies for Children with Cancer (ITCC), which has as its aim to develop novel therapies for paediatric tumours. A significant number of new studies have opened since 2010, improving the treatment opportunities for our children. Results of recently closed trials show the contribution of Spanish investigators, the introduction of molecularly targeted agents, and their benefits. Conclusions: The activity in clinical trials has increased in the years analysed. The SEHOP is committed to develop and participate in collaborative academic trials, in order to help in the advancement and optimisation of existing therapies in paediatric cancer. Bautista F, Gallego S, Canete A, Mora J, Diaz De Heredia C, Cruz O, et al. Early clinical trials in paediatric oncology in Spain: a nationwide perspective. An Pediatr. 2017 Sep;87(3):155-63. Epub 2017 Mar 6. 10.1016/j.anpedi.2016.07.007 1696-4608 1695-4033 Anales de Pediatria http://hdl.handle.net/20.500.13003/17455 28279690 L614713739 2-s2.0-85014543739 http://hdl.handle.net/20.500.12105/20476 411045700006 Paediatric haematology and oncology Early phase clinical trials Drug development Personalised medicine Early clinical trials in paediatric oncology in Spain: a nationwide perspective